Sun Pharmaceutical Industries has announced the launch of FEXUCLUE, a novel potassium-competitive acid blocker (P-CAB), in India. The drug, available in 40 mg tablets, is approved as a new treatment ...

Indian drugmaker Sun Pharmaceutical Industries (BSE: 524715) revealed it has launched fexuprazan tablets 40mg in India under the brand name Fexuclue, which is a novel potassiumcompetitive acid blocker ...

Sun Pharmaceutical Industries on Monday said it has introduced a medication for the treatment of Erosive Esophagitis of all grades. The Mumbai-based drug major, in a statement, said it has launched ...

The Nippon India Pharma Fund - Growth has an AUM of ... The top holdings of the fund include Sun Pharmaceutical Industries, Divis Laboratories, Lupin & Cipla. The major sectors where the fund ...

Canara Robeco Equity Hybrid Fund (IDCW-M) 112.53 6,60,000 1.08 Canara Robeco Equity Hybrid Fund - Direct (IDCW-M) 112.53 6,60,000 1.08 Canara Robeco Equity Hybrid Fund (G) 112.53 6,60,000 1.08 Canara ...

US President Trump's tariff announcements have created both uncertainty and opportunity for India's pharmaceutical sector. Experts emphasize the need for strategic action, innovation, and ...

India’s annual drug and pharmaceutical exports touched a record $30 billion in FY25 bolstered by a 31% year-on-year surge in March. At $30467.32 million, the exports were 9.39% higher than the $ ...

View all information regarding the medicines that are manufactured by Sun Pharma including its generic drug name, trade name, how to use, the price, and its composition.

Sun Pharmaceutical Industries, operating in the Pharmaceuticals sector and classified as a Largecap on the BSE, currently has its share price at ₹1751.95. The stock has experienced fluctuations ...

Sun Pharmaceutical Industries Ltd ... after the US President Donald Trump said that there'll be tariff on pharma products which are not seen before. The US is assessing the pharma sector as a separate ...

“We are positive on these three stocks—Sun Pharma, Dr Reddy’s, and Lupin—despite the tariff announcements. India remains the ‘pharmacy of the world,’ and there’s no challenge to its ...